BiotechTV

•

Channel • 5 Shows

Life Sciences

Life Sciences

Updated 1d ago
Life Sciences

Life Sciences

Updated Biweekly
Life Sciences

Life Sciences

Updated Dec 2
Life Sciences

Life Sciences

Updated May 8
Life Sciences

Life Sciences

Updated Dec 19

1D AGO

Episode 31: Polaris Partners' Amy Schulman

She describes her career beginnings as a lawyer, which led to general counsel and business unit head roles at Pfizer, and then joining the VC world at Polaris Partners (at Bob Langer's urging). She discusses the firm's investment philosophy, the nuances behind how companies choose lead assets, and the cycles biotech has been through over the last ten years. Plus, other roles she currently serves, including being the chair of Alnylam.

1d ago

•

1h 3m
1D AGO

A deep dive discussion on Abivax with Truist Senior Biotech Analyst Gregory Renza

We discuss the upcoming maintenance data, commercial prospects, Crohn's, and buyout prospects.

1d ago

•

45 min
DEC 9

ASH 2025: Kelonia Therapeutics presented convincing late-breaking data at ASH today from its initial patients in multiple myeloma suggesting that in vivo CAR-T is on track to be a next innovation

Founder and CEO Kevin Friedman describes Kelonia's approach, which uses a lentivirus for delivery, and discusses differentiating features of in vivo CAR-T platforms. He walks us through today's data and highlights what is next.

Dec 9

•

19 min
DEC 1

Episode 29: Averin Managing Partner David Berry

He describes his early life and education, 18 years of company building at Flagship Pioneering, founding Averin (previously called Bedford Bridge) with his brother, and investing at the intersection of healthcare and technology.

Dec 1

•

1h 19m
$ASH 2025: MaaT Pharma's microbiome based treatment for refractory GVHD is in front of EMA right now for a possible 2026 approval - the pivotal data was presented in an oral at ASH this week$

DEC 9

ASH 2025: MaaT Pharma's microbiome based treatment for refractory GVHD is in front of EMA right now for a possible 2026 approval - the pivotal data was presented in an oral at ASH this week

Founder and CEO Hervé Affagard walks us through how this treatment works and highlights the ASH presentation and one year survival data the company has accrued. Plus, how compassionate use is going in the United States.

Dec 9

•

10 min
DEC 8

ASH 2025: Kura Oncology CEO Troy Wilson discusses the recent approval of the company's menin inhibitor (KOMZIFTI) in R/R NPM1 mutated AML, and highlights ASH data in the front line setting

He discusses the profile of the therapy both as monotherapy and in combination, and compares and contrasts it to competitor data. Plus, the success factors behind Avidity Biosciences, which he co-founded and was recently acquired by Novartis for $12 billion.

Dec 8

•

13 min
DEC 7

ASH 2025: Disc Medicine CEO John Quisel walks us through the RALLY-MF Phase 2 trial data of DISC-0974 in anemia of myelofibrosis

He says that this interim update, which is studying 50mg every 4 weeks for up to 6 treatments, is showing response rates in line with an earlier dose escalation study that was presented at ASH last year. Plus, a quick regulatory update on bitopertin.

Dec 7

•

18 min
OCT 6

Episode 26: venBio's Corey Goodman

Corey Goodman shares learnings for his career in biotech, including working in academia, biotech, pharma, and as a venture capital investor. He describes the unique learnings from all of them and why he is thankful that he has experienced these different components of life sciences.

Oct 6

•

1h 21m
DEC 8

ASH 2025: Nurix CEO Arthur Sands discusses his company's BTK degrader data at ASH, and highlights the benefits of degraders more broadly in oncology and I&I

He describes two studies Nurix presented for bexobrutideg at ASH, and also discusses the pivotal DAYBreak study that has already been initiated. Plus, his take on today's STAT6 competitor data and how he feels about IRAK4.

Dec 8

•

17 min
APR 7

Elias Zerhouni and Andy Plump discuss the future of multispecific biologics

Interviewed by Andy Plump, President of R&D at Takeda, Dr. Zerhouni discusses the rationale for multispecifics and the science behind them. They also discuss the differences between pharma and biotech, keys to being an effective R&D leader, and advice for both young and experienced people in their careers.

Apr 7

•

36 min

BiotechTV covers the biotechnology sector through news, stories, podcasts, and educational videos.

Website

BiotechTV

Top Shows

Episode 31: Polaris Partners' Amy Schulman

A deep dive discussion on Abivax with Truist Senior Biotech Analyst Gregory Renza

ASH 2025: Kelonia Therapeutics presented convincing late-breaking data at ASH today from its initial patients in multiple myeloma suggesting that in vivo CAR-T is on track to be a next innovation

Episode 29: Averin Managing Partner David Berry

ASH 2025: MaaT Pharma's microbiome based treatment for refractory GVHD is in front of EMA right now for a possible 2026 approval - the pivotal data was presented in an oral at ASH this week

ASH 2025: Kura Oncology CEO Troy Wilson discusses the recent approval of the company's menin inhibitor (KOMZIFTI) in R/R NPM1 mutated AML, and highlights ASH data in the front line setting

ASH 2025: Disc Medicine CEO John Quisel walks us through the RALLY-MF Phase 2 trial data of DISC-0974 in anemia of myelofibrosis

Episode 26: venBio's Corey Goodman

ASH 2025: Nurix CEO Arthur Sands discusses his company's BTK degrader data at ASH, and highlights the benefits of degraders more broadly in oncology and I&I

Elias Zerhouni and Andy Plump discuss the future of multispecific biologics

About

BiotechTV

Top Shows

Top Episodes

About